- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04639635
CNGB1 and Allied Disorders
February 29, 2024 updated by: Stephen H. Tsang, Columbia University
Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders
Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision.
Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP).
RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes.
Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP.
In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells.
This provides a wide window of opportunity for the identification of patients and initiation of treatment.
Our efforts are directed toward developing gene therapy as a treatment.
To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France
- Recruiting
- Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts
-
Contact:
- Isabelle Audo, MD, PhD
- Phone Number: +33 1 40 02 14 30
- Email: isabelle.audo@inserm.fr
-
Contact:
- Camille Andrieu, MD
- Phone Number: +33 1 40 02 14 51
- Email: candrieu@15-20.fr
-
Principal Investigator:
- Isabelle Audo, MD, PhD
-
-
-
-
-
Tuebingen, Germany
- Recruiting
- Eberhard Karls University Tubingen
-
Contact:
- Laura Kuehlewein, MD
- Phone Number: +49 07071 29-88088
- Email: laura.kuehlewein@med.uni-tuebingen.de
-
Contact:
- Katarina Stingl, MD
- Phone Number: +49 7071 29 87421
- Email: katarina.stingl@med.uni-tuebingen.de
-
Principal Investigator:
- Eberhart Zrenner, MD
-
-
Bavaria
-
München, Bavaria, Germany, 80336
- Recruiting
- Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich
-
Contact:
- Claudia Priglinger, PD Dr.
- Phone Number: +49 (0)89 4400 53717
- Email: claudia.priglinger@med.uni-muenchen.de
-
Principal Investigator:
- Maximilian Gerhardt, MD
-
Contact:
- Stefan May
- Phone Number: +49 (0)89 4400-53146
- Email: Stefan.May@med.uni-muenchen.de
-
Principal Investigator:
- Stylianos Michalakis, PhD
-
-
-
-
-
London, United Kingdom
- Not yet recruiting
- Moorfields Eye Hospital NHS Foundation Trust
-
Contact:
- Simona D Esposti, MD
- Phone Number: (+44) 207 566 2263
- Email: s.esposti@nhs.net
-
Contact:
- Omar Mahroo, PhD
- Phone Number: (+44) 207 566 2263
- Email: o.mahroo@ucl.ac.uk
-
Principal Investigator:
- Simona D Esposti, MD
-
-
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Dr. Stephen H. Tsang
-
Contact:
- Stephen H Tsang, MD, PhD
- Phone Number: 212-342-1186
- Email: sht2@columbia.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Wills Eye Hospital
-
Contact:
- Rebecca Procopio, CGC
- Phone Number: 267-733-9681
- Email: rprocopio@willseye.org
-
Contact:
- Tobin BT Thuma, DO
- Phone Number: 215-928-3240
- Email: tthuma@willseye.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients are expected to present to the clinic at all age groups; enrollment of subjects <18 years of age will be obtained by informed consent in the company of a parent or legal guardian.
There will also be no gender-or ethnic/racial specific inclusion criteria.
The enrollment of non-English speaking subjects is not expected.
Description
Inclusion Criteria:
- Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic
- Must be able to commit to 4 follow-up study visits (3 years)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
We will be looking to identify what the best outcome measurements will be for CNGB1-RP in order to use these measurements in a future clinical trial.
Time Frame: 2 days, 1 time per year, for 3 years
|
Both structural imaging and functional tests will be used to characterize the natural history progression of CNGB1-RP.
|
2 days, 1 time per year, for 3 years
|
Medmont Dark Adapted Chromatic (DAC) Automated Perimeter
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Full-field ERG (ISCEV Protocol)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Optical Coherence Tomography (OCT)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Fundus Autofluorescence (FAF)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Near-infrared fundus autofluorescence (NIR-AF)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Quantitative Fundus Autofluorescence (qAF)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best-corrected Visual Acuity (BCVA)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Complete Ophthalmic Exam
Time Frame: 2 time per year, for 3 years
|
2 time per year, for 3 years
|
|
Color Fundus Photos
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
MAIA Microperimetry
Time Frame: 1 time per year, for 3 years
|
if available
|
1 time per year, for 3 years
|
NIDEK Microperimetry
Time Frame: 1 time per year, for 3 years
|
if available
|
1 time per year, for 3 years
|
Goldman Kinetic Visual Field
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Light-adapted Static Perimetry
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Panel D-15 Colour Vision (desat.)
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Dark-adapted Chromatic Perimetry
Time Frame: 1 time per year, for 3 years
|
1 time per year, for 3 years
|
|
Full-field Stimulus Testing (FST)
Time Frame: 1 time per year, for 3 years
|
Optional
|
1 time per year, for 3 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Demographics/medical history
Time Frame: 1 time only at baseline
|
1 time only at baseline
|
Concomitant medications/adverse events
Time Frame: 1 time only at baseline
|
1 time only at baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2019
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
August 7, 2020
First Submitted That Met QC Criteria
November 16, 2020
First Posted (Actual)
November 20, 2020
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAS1160
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa Associated With CNGB1 Mutations
-
Innostellar Biotherapeutics Co.,LtdActive, not recruitingInherited Retinal Dystrophy Associated With RPE65 MutationsChina
-
Guangxi Medical UniversityCompletedFull Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach | Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
-
Cook Children's Health Care SystemNo longer availableDravet Syndrome | Epileptic Encephalopathies Associated With SCN1A MutationsUnited States
-
University of Alabama at BirminghamNational Institutes of Health (NIH); Mereo BioPharmaCompletedEmphysema or COPD | Alpha-1 Antitrypsin Deficiency (AATD) | Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I MutationsUnited States
-
Mayo ClinicAstellas Pharma Inc; Casimir, LLCRecruitingMitochondrial Diseases | Mitochondrial Myopathies | Kearns-Sayre Syndrome | Mitochondrial DNA Mutation | Chronic Progressive External Ophthalmoplegia With MyopathyUnited States
-
National Human Genome Research Institute (NHGRI)RecruitingMetabolic Disease | Purine-Pyrimidine Metabolism | AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2 | UNG, OMIM *191525, Hyper-IgM Syndrome 5 | NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency | UMPS, OMIM *613891, Orotic Aciduria | DHODH, OMIM *126064,... and other conditionsUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
Clinical Trials on No intervention, this is a natural history progression study
-
QuantalX NeuroscienceCompletedHealthy | Hemorrhage | Cognitive Impairment | Dementia | Fibromyalgia | TBI (Traumatic Brain Injury) | Cognitive Decline | Concussion, Brain | MS (Multiple Sclerosis) | Adhd | CVA | ABD | MciIsrael
-
University Hospital, BonnGenentech, Inc.CompletedEye Diseases | Age-related Macular Degeneration | Geographic Atrophy | AtrophyGermany
-
Boston IVFCompleted
-
Nicoline LøkkenCompleted
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)CompletedThe Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural ConnectivityDrug Use | Neurodevelopmental Abnormality | Cannabis Use Disorder | PREG1 | Fetal Exposure During PregnancyUnited States
-
Kardium Inc.St. Paul's Hospital, CanadaCompletedAtrial FibrillationCanada
-
Rutgers, The State University of New JerseyNational Institute of Neurological Disorders and Stroke (NINDS)CompletedDepression | Parkinson's Disease | AnxietyUnited States
-
King's College LondonCompleted
-
The University of Texas Health Science Center,...CompletedWound InfectionUnited States